Breaking News

Biothera Names Biomarker Development VP

By Kristin Brooks | January 28, 2014

Maimonis to lead development and commercialization of assays for Phase III cancer drug

Peter J. Maimonis, Ph.D. has been appointed vice president of biomarker development at Biothera and will lead the development and commercialization of assays for the company’s Phase III cancer immunotherapy, Imprime PGG. Dr. Maimonis previously held senior positions with various pharmaceutical and diagnostic companies, including senior director, Cancer Cell Biology at On-Q-ity, vice president of Biology R&D at Decision Biomarkers, and associate director for Oncology Research at Bayer Health Care.
“For the past quarter century Dr. Maimonis has focused on the discovery and development of oncology biomarkers, companion diagnostics and assays,” said Dan Conners, president of Biothera’s Pharmaceutical Group. “His expertise is a perfect fit for Biothera as we advance the science of the predictive biomarker for Imprime PGG.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks